Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) saw unusually-strong trading volume on Thursday . 2,690,925 shares changed hands during mid-day trading, an increase of 0% from the previous session’s volume of 2,685,224 shares.The stock last traded at $6.4550 and had previously closed at $6.94.
Analysts Set New Price Targets
TSHA has been the subject of a number of recent analyst reports. Chardan Capital reiterated a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Bank of America upped their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Pivotal Research set a $14.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $12.38.
Get Our Latest Stock Report on Taysha Gene Therapies
Taysha Gene Therapies Stock Performance
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current year.
Insider Buying and Selling at Taysha Gene Therapies
In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the sale, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.
Institutional Investors Weigh In On Taysha Gene Therapies
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vestal Point Capital LP increased its stake in shares of Taysha Gene Therapies by 150.0% in the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after buying an additional 8,250,000 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in shares of Taysha Gene Therapies in the second quarter worth $11,178,000. Barclays PLC increased its holdings in Taysha Gene Therapies by 1,042.8% in the third quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after purchasing an additional 4,697,611 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Taysha Gene Therapies during the 4th quarter worth $20,471,000. Finally, State Street Corp raised its position in Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after purchasing an additional 3,553,619 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.
Featured Stories
- Five stocks we like better than Taysha Gene Therapies
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
- Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story
- Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?
- Micron’s HBM Surge Could Redefine the AI Growth Story
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
